Biblio Discovery — Demo Discovery Service

20 results for "Mattea Reinisch"

Showing 1–20 · 0.28 seconds · RSS

  1. Journal Article

    The INTREST registry: protocol of a multicenter prospective cohort study of predictors of women’s response to integrative breast cancer treatment

    Heidemarie Haller; Petra Voiß; Holger Cramer et al.

    BMC Cancer, Vol. 21 No. 1 · 2021 · English · DOAJ Scopus

    Abstract Background Cancer registries usually assess data of conventional treatments and/or patient survival. Beyond that, little is known about the influence of other predictors of treatment response related to the use of complementary therapies (CM) and lifestyle factors affecting patients’…

  2. Journal Article

    Two progressed malignant phyllodes tumors of the breast harbor alterations in genes frequently involved in other advanced cancers

    Mattea Reinisch; Sherko Kuemmel; Elisabeth Breit et al.

    Orphanet Journal of Rare Diseases, Vol. 16 No. 1 · 2021 · English · DOAJ Scopus

    Abstract Background The genomic landscape of phyllodes tumors (PTs) of the breast is not well defined, especially in patients with advanced disease. To shed light on this topic, paired primary and progressed tumor samples from two patients with malignant PTs were subjected to next-generation…

  3. Journal Article

    Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany

    Mattea Reinisch; Simona Bruzas; Jennifer Spoenlein et al.

    Therapeutic Advances in Medical Oncology, Vol. 15 · 2023 · English · DOAJ Scopus

    Background: Sacituzumab govitecan has been recently approved by the USFDA and EMA for the treatment of patients with metastatic triple-negative breast cancer (mTNBC). We report real-world safety and effectiveness in patients with mTNBC receiving sacituzumab govitecan treatment at a breast cancer…

  4. Journal Article

    Autologous vs. implant-based breast reconstruction after skin- and nipple-sparing mastectomy—A deeper insight considering surgical and patient-reported outcomes

    Maxi von Glinski; Nikla Holler; Sherko Kümmel et al.

    Frontiers in Surgery, Vol. 9 · 2022 · English · DOAJ Scopus

    IntroductionAutologous (ABR) and implant-based breast reconstruction (IBR) represent the most common procedures after skin- and nipple-sparing mastectomy. This cross-sectional study is a comprehensive analysis of ABR and IBR considering surgical and patient-reported outcomes.Patients and…

  5. Journal Article

    Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8

    Guy Jerusalem; Aleix Prat; Roberto Salgado et al.

    Breast, Vol. 72 · 2023 · English · DOAJ Scopus

    Background: Preclinical data suggest synergistic activity with the combination of programmed death-1 and cyclin-dependent kinase 4/6 blockade in oestrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2–) breast cancer. The noncomparative phase 1b/2 CheckMate 7A8 study…

  6. Journal Article

    Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy

    Mattea Reinisch; Simona Bruzas; Oleg Gluz et al.

    Molecular Oncology, Vol. 17 No. 6 · 2023 · English · DOAJ Scopus

    The utility of multigene expression assays in advanced (≥ 4 positive lymph nodes) early breast cancer (EBC) is limited. We conducted exploratory transcriptomic analysis of 758 genes (Breast Cancer 360 panel, nCounter® platform; NanoString) in primary tumor samples collected during a phase 3 trial…

  7. Journal Article Full text

    Ultrasound-Visible 3D Nickel–Titanium Clip for Tumor Localization After Neoadjuvant Therapy in Early Breast Cancer: A Prospective Multicenter Real-World Study

    Mattea Reinisch; Efstathia Cremer; Kilian Pankert et al.

    Diagnostics, Vol. 16 No. 17 · 2026 · English · DOAJ Scopus

    Background: Neoadjuvant systemic therapy (NST) enables tumor downsizing and increases the feasibility of breast-conserving surgery (BCS) in patients with early breast cancer (EBC). Reliable tumor localization after NST remains challenging, particularly in patients with a complete clinical response…

  8. Journal Article

    Gene signatures in patients with early breast cancer and relapse despite pathologic complete response

    Simona Bruzas; Oleg Gluz; Nadia Harbeck et al.

    npj Breast Cancer, Vol. 8 No. 1 · 2022 · English · DOAJ Scopus

    Abstract A substantial minority of early breast cancer (EBC) patients relapse despite their tumors achieving pathologic complete response (pCR) after neoadjuvant therapy. We compared gene expression (BC360; nCounter® platform; NanoString) between primary tumors of patients with post-pCR relapse (N…

  9. Journal Article

    RESPONDER – diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial

    Joerg Heil; Peter Sinn; Hannah Richter et al.

    BMC Cancer, Vol. 18 No. 1 · 2018 · English · DOAJ Scopus

    Abstract Background Neoadjuvant chemotherapy (NACT) is a standard approach of the multidisciplinary treatment of breast cancer. Depending on the biological subtype a pathological complete response in the breast (bpCR) can be achieved in up to 60% of the patients. However, only limited accuracy can…

  10. Journal Article

    Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy

    Jens Huober; Marion van Mackelenbergh; Andreas Schneeweiss et al.

    npj Breast Cancer, Vol. 9 No. 1 · 2023 · English · DOAJ Scopus

    Abstract This retrospective pooled analysis aims to identify factors predicting relapse despite a pathologic complete response (pCR) in patients with breast cancer (BC). 2066 patients with a pCR from five neoadjuvant GBG/AGO-B trials fulfill the inclusion criteria of this analysis. Primary endpoint…

  11. Journal Article

    Surgical axillary intervention after neoadjuvant systemic therapy (NST) for early-stage breast cancer – Clinical significance of micrometastases: Data from five neoadjuvant studies

    Fabienne J. Warnecke; Johannes Holtschmidt; Andreas Schneeweiss et al.

    Breast, Vol. 89 · 2026 · English · DOAJ Scopus

    Introduction: Axillary surgery for early breast cancer has become less aggressive. However, the optimal approach after neoadjuvant systemic therapy (NST) remains uncertain and depends on axillary response. Especially the significance of nodal micrometastases (ypN1mi) after NST regarding oncological…

  12. Journal Article

    Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs

    Niklas Gremke; Isabelle Besong; Alina Stroh et al.

    Signal Transduction and Targeted Therapy, Vol. 10 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Activating PIK3CA mutations, present in up to 40% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (Her2−) breast cancer (BC) patients, can be effectively targeted with the alpha isoform-specific PI3K inhibitor Alpelisib. This treatment significantly…

  13. Journal Article

    Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto

    Elena Laakmann; Isabell Witzel; Peter A. Fasching et al.

    Breast Cancer Research, Vol. 21 No. 1 · 2019 · English · DOAJ Scopus

    Abstract Background The incidence of central nervous system (CNS) metastases in breast cancer patients is rising and has become a major clinical challenge. Only few data are published concerning risk factors for the development of CNS metastases as a first site of metastatic disease in breast…

  14. Journal Article

    Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study

    Mattea Reinisch; Michael Untch; Rolf Mahlberg et al.

    Breast, Vol. 66 · 2022 · English · DOAJ Scopus

    Background: Trastuzumab given intravenously in combination with chemotherapy is standard of care for patients with early HER2-positive breast cancer (BC). Different randomised studies have shown equivalent efficacy of a subcutaneous injection into the thigh compared to the intravenous formulation…

  15. Journal Article

    Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer

    Marion T. Van Mackelenbergh; Nicole Pfarr; Karsten Weber et al.

    npj Breast Cancer, Vol. 12 No. 1 · 2026 · English · DOAJ Scopus

    Abstract The presented study investigated the relevance of mutations in 17 cancer genes and response to neoadjuvant chemotherapy in two clinical cohorts of HER2+ breast cancer. 364 samples from HER2+ tumors of the neoadjuvant studies GeparTrio (no anti-HER2 treatment, n = 71) and GeparSepto (dual…

  16. Journal Article

    GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer

    Volker Möbus; Hans-Joachim Lück; Ekkehart Ladda et al.

    npj Breast Cancer, Vol. 10 No. 1 · 2024 · English · DOAJ Scopus

    Abstract GAIN-2 trial evaluated the optimal intense dose-dense (idd) strategy for high-risk early breast cancer. This study reports the secondary endpoints pathological complete response (pCR) and overall survival (OS). Patients (n = 2887) were randomized 1:1 between idd epirubicin, nab-paclitaxel…

  17. Journal Article Full text

    Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

    David W. Miles; Joseph Gligorov; Fabrice André et al.

    Annals of Oncology · 2021 · English · OpenAlex Scopus

    BACKGROUND: In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in the intention-to-treat (ITT) and programmed…

  18. Journal Article

    HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN

    Gilda Schmidt; Oleg Gluz; Matthias Christgen et al.

    Breast Cancer Research, Vol. 27 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Background New data show that not only HER2-overexpressing breast cancer (BC) tumors but also HER2-low tumors, classically considered as HER2-negative, respond to HER2-targeting antibody–drug-conjugates. Our objective was to analyze the prevalence of HER2-low BC in a pooled analysis of…

  19. Journal Article

    AGO Breast Panel Recommendations for the use of treatment-relevant biomarkers in early and advanced breast cancer—2026 Update

    Andreas Hartkopf; Ute-Susann Albert; Rupert Bartsch et al.

    Breast, Vol. 89 · 2026 · English · DOAJ Scopus

    Biomarkers are integral to modern breast cancer management by providing essential information for prognosis and treatment selection. This review presents the 2026 update of the recommendations of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) on…

  20. Journal Article

    Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)

    Walter P. Weber; Zoltan Matrai; Stefanie Hayoz et al.

    Breast, Vol. 60 · 2021 · English · DOAJ Scopus

    Aim: We developed tailored axillary surgery (TAS) to reduce the axillary tumor volume in patients with clinically node-positive breast cancer to the point where radiotherapy can control it. The aim of this study was to quantify the extent of tumor load reduction achieved by TAS. Methods…